We spoke to new Sterling Energy CEO Tony Hawkins about the latest changes happening at the company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 165.00
Bid: 164.00
Ask: 166.00
Change: -3.00 (-1.79%)
Spread: 2.00 (1.22%)
Open: 166.00
High: 169.00
Low: 165.00
Yest. Close: 168.00
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

24 Jul 19 12:58

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

9 Jul 19 09:26

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

18 Apr 19 11:52

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

14 Mar 19 14:47

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

14 Mar 19 11:37

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

25 Feb 19 11:41

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

22 Oct 18 11:53

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

22 Oct 18 09:20

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

25 Sep 18 13:48

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

15 Mar 18 12:57

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

12 Oct 16 09:52

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

22 Mar 16 11:07

Earnings, Trading Statements Calendar - Week Ahead

21 Mar 16 16:06

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

12 Nov 15 11:35

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

16 Sep 15 13:03

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.